Glaxo, SK Bioscience report positive Covid vaccine results

Bloomberg: GlaxoSmithKline Plc and SK Bioscience Co said they’re seeking authorization for their Covid vaccine in South Korea after positive results in a late-stage study.

The companies said the shot met its objectives in the trial and an agreement has been signed with Korean authorities to supply 10 million doses. SK Bioscience conducted a trial in 4,037 adults across six countries and said it found that the vaccine candidate demonstrated superior results compared with AstraZeneca Plc’s Vaxzevria.

“As the Covid-19 pandemic continues to evolve, a variety of vaccines will be needed to meet the health needs across the globe,” Roger Connor, president of GSK’s vaccines business, wrote in a statement.

Glaxo is also developing a separate Covid vaccine with French drugmaker Sanofi.